Terms: = Sarcomas AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
626 results:
1. Vitexicarpin Induces Apoptosis and Inhibits Metastatic Properties via the AKT-PRAS40 Pathway in Human Osteosarcoma.
Yun HM; Kwon HS; Lee JY; Park KR
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612399
[TBL] [Abstract] [Full Text] [Related]
2. Circ_0002669 promotes osteosarcoma tumorigenesis through directly binding to MYCBP and sponging miR-889-3p.
Zhang Y; Zhan Y; Liu Z; Guo H; Liu D; Chen C
Biol Direct; 2024 Apr; 19(1):25. PubMed ID: 38570856
[TBL] [Abstract] [Full Text] [Related]
3. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract] [Full Text] [Related]
4. Combined SET7/9 and cdk4 inhibition act synergistically against osteosarcoma.
Shi Y; Wang Z; Shao Y; Guang Q; Zhang J; Liu B; Wu C; Wang Y; Sui P
Biochem Biophys Res Commun; 2024 May; 708():149808. PubMed ID: 38520914
[TBL] [Abstract] [Full Text] [Related]
5. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
[TBL] [Abstract] [Full Text] [Related]
6. PRMT5 is an actionable therapeutic target in cdk4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
[TBL] [Abstract] [Full Text] [Related]
7. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Tan Q; Gao R; Zhang X; Yang J; Xing P; Yang S; Wang D; Wang G; Wang S; Yao J; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2024 Feb; 73(3):47. PubMed ID: 38349411
[TBL] [Abstract] [Full Text] [Related]
8. A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Huang H; Zhang H; Cao B
Thorac Cancer; 2024 Feb; 15(5):427-433. PubMed ID: 38211967
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
[TBL] [Abstract] [Full Text] [Related]
10. Rare myxoid pleomorphic liposarcoma: a case report and literature review.
Shen Y; Zhao L; Li A; Peng Q; Liu Q; Wang L; Liu Z
J Clin Pathol; 2024 Apr; 77(5):358-362. PubMed ID: 38123348
[TBL] [Abstract] [Full Text] [Related]
11. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
Somaiah N; Tap W
Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
[TBL] [Abstract] [Full Text] [Related]
12. To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma.
Weiss MC; Eulo V; Van Tine BA
Clin Cancer Res; 2024 Feb; 30(4):649-651. PubMed ID: 38064245
[TBL] [Abstract] [Full Text] [Related]
13. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
14. cdk4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.
Wang J; Calizo A; Zhang L; Pino JC; Lyu Y; Pollard K; Zhang X; Larsson AT; Conniff E; Llosa NJ; Wood DK; Largaespada DA; Moody SE; Gosline SJ; Hirbe AC; Pratilas CA
Sci Adv; 2023 Nov; 9(47):eadg8876. PubMed ID: 38000020
[TBL] [Abstract] [Full Text] [Related]
15. Identification of hub genes and pathways associated with cellular senescence in diabetic foot ulcers via comprehensive transcriptome analysis.
Huang Y; Wang D; Zhang W; Yuan X; Li K; Zhang Y; Zeng M
J Cell Mol Med; 2024 Jan; 28(1):e18043. PubMed ID: 37985432
[TBL] [Abstract] [Full Text] [Related]
16. SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).
Movva S; Matloob S; Handorf EA; Choy E; Merriam P; Flieder DB; Cai KQ; Zhou Y; Tetzlaff ED; Pagan C; Barker E; Veggeberg R; Zumpano D; Rink L; von Mehren M; George S
Clin Cancer Res; 2024 Jan; 30(2):315-322. PubMed ID: 37967116
[TBL] [Abstract] [Full Text] [Related]
17. Osteosarcomas With Few Chromosomal Alterations or Adult Onset Are Genetically Heterogeneous.
Difilippo V; Saba KH; Styring E; Magnusson L; Nilsson J; Nathrath M; Baumhoer D; Nord KH
Lab Invest; 2024 Jan; 104(1):100283. PubMed ID: 37931683
[TBL] [Abstract] [Full Text] [Related]
18. cdk4/6 Inhibition With Lerociclib is a Potential Therapeutic Strategy for the Treatment of Pediatric sarcomas.
Julson JR; Horton SC; Quinn CH; Beierle AM; Bownes LV; Stewart JE; Aye J; Yoon KJ; Beierle EA
J Pediatr Surg; 2024 Mar; 59(3):473-482. PubMed ID: 37919169
[TBL] [Abstract] [Full Text] [Related]
19. Phase II trial of cdk4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of cdk4/ CDKN2A.
Martin-Broto J; Martinez-Garcia J; Moura DS; Redondo A; Gutierrez A; Lopez-Pousa A; Martinez-Trufero J; Sevilla I; Diaz-Beveridge R; Solis-Hernandez MP; Carnero A; Perez M; Marcilla D; Garcia-Foncillas J; Romero P; Fernandez-Jara J; Lopez-Lopez D; Arribas I; Hindi N
Signal Transduct Target Ther; 2023 Oct; 8(1):405. PubMed ID: 37875500
[TBL] [Abstract] [Full Text] [Related]
20. Biology and Management of Deep-seated Atypical Lipomatous Tumor of the Extremities.
Nishio J; Nakayama S; Chijiiwa Y; Aoki M
Anticancer Res; 2023 Oct; 43(10):4295-4301. PubMed ID: 37772567
[TBL] [Abstract] [Full Text] [Related]
[Next]
